Novo Nordisk falls after Metsera shareholders vote for Pfizer's offer

U.S.-listed shares of Danish drugmaker Novo Nordisk NOVOb.CO fall 1.4% to $49.54, while Pfizer's were up 1.4% at $26.21

Metsera MTSR.O shareholders approved Pfizer's PFE.N takeover offer worth up to $10 billion, allowing the U.S. pharma giant re-entry into the lucrative obesity treatment market after a fierce bidding war with Wegovy-maker Novo Nordisk

Novo said on Saturday it would not be making an increased offer

Including session's moves, NVO down 42.8%, PFE down 2.6% YTD while MTSR shares have climbed more than threefold since their January IPO